[Combination treatment of insulin dependent elderly diabetics (type II diabetes) with the sulfonylurea compound glibenclamide].
About 20 per cent of our patients between sixty and eighty years suffer from maturity onset diabetes including many subjects with an insulin requiring form. Beside cases of secondary failure were those with increased insulin resistance. In order to improve low compliance, a clear therapy is desirable. Therefore a combination of sulfonylurea with insulin is suitable instead of a repeated insulin-delivery by day. This way of treatment is known since the late fifties and its application increases in the last years. These results suggest that a combination with glibenclamide leads to a decrease of insulin-requirement. This is true both for secondary failure and difficult insulin monotherapy. More than 80 per cent of those patients who needed a twice by day insulin injection now do with only one delivery. The course of daily blood sugar profile is clearly smoothed.
D000368:Aged; D001786:Blood Glucose / Q000378:metabolism; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy*; D004359:Drug Therapy, Combination; D005260:Female; D005905:Glyburide / Q000627:therapeutic use*; D006801:Humans; D007328:Insulin / Q000627:therapeutic use*; D008297:Male
D001786:Blood Glucose; D007328:Insulin; D005905:Glyburide
Kombinationsbehandlung insulinpflichtiger Altersdiabetiker (Typ-II-Diabetes) mit dem Sulfonylharnstoff Glibenclamid.